专栏咏竹坊

Yidu suffers from lingering Covid chill

This article only represents the author's own views.

Chinese companies have generally rebounded since Beijing scrapped its “zero Covid” policy at the end of last year, ending punishing control measures that were wreaking havoc on business. But medical big data specialist Yidu Tech Inc. (2158.HK) is defying that rule with an accelerating business slump after its revenue started contracting earlier last year.

The company, whose software solutions are used by medical institutions for functions like assisting in disease diagnosis and drug development, saw its revenue tumble by 55% to 330 million yuan ($46 million) in the six months through March, accelerating from a 5.5% decline for the previous six-month period through last September, according to calculations using its latest annual report released last Friday and previous interim report.

您已阅读14%(846字),剩余86%(5318字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

咏竹坊

咏竹坊(官网链接)提供在香港和美国上市的manbetx3.0 企业相关新闻,重点关注中小企业和筹备上市的公司。

Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.

相关文章

相关话题

设置字号×
最小
较小
默认
较大
最大
分享×